Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
Darren K. McGuire, Weichung Shih, Francesco Cosentino, et al.
JAMA Cardiology (2020) Vol. 6, Iss. 2, pp. 148-148
Open Access | Times Cited: 880

Showing 26-50 of 880 citing articles:

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S191-S202
Open Access | Times Cited: 202
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 180
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention
Nathan D. Wong, Naveed Sattar
Nature Reviews Cardiology (2023) Vol. 20, Iss. 10, pp. 685-695
Closed Access | Times Cited: 180
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S179-S218
Open Access | Times Cited: 177
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L. Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Circulation (2022) Vol. 145, Iss. 19, pp. 1460-1470
Open Access | Times Cited: 176
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, et al.
Circulation (2021) Vol. 145, Iss. 6, pp. 437-447
Open Access | Times Cited: 169
Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 169
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S144-S174
Open Access | Times Cited: 165
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 119-129
Open Access | Times Cited: 140
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S175-S184
Closed Access | Times Cited: 138
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Clifford J. Bailey, Caroline Day, Srikanth Bellary
Current Diabetes Reports (2022) Vol. 22, Iss. 1, pp. 39-52
Open Access | Times Cited: 138
Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity.
Robert J. Henning
PubMed (2021) Vol. 11, Iss. 4, pp. 504-529
Closed Access | Times Cited: 134
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
Stefan James, David Erlinge, Robert F. Storey, et al.
NEJM Evidence (2023) Vol. 3, Iss. 2
Open Access | Times Cited: 127
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Lucia Mazzolai, Gisela Teixidó‐Turà, Stefano Lanzi, et al.
European Heart Journal (2024)
Open Access | Times Cited: 122
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S219-S230
Open Access | Times Cited: 113
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 111
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L. Neuen, Megumi Oshima, Vlado Perkovic, et al.
European Heart Journal (2021) Vol. 42, Iss. 48, pp. 4891-4901
Open Access | Times Cited: 107
Diabetes and Stroke: What Are the Connections?
Ofri Mosenzon, Alice Cheng, Alejandro A. Rabinstein, et al.
Journal of Stroke (2023) Vol. 25, Iss. 1, pp. 26-38
Open Access | Times Cited: 105
Disorders of lipid metabolism. Clinical Guidelines 2023
М. В. Ежов, В. В. Кухарчук, И. В. Сергиенко, et al.
Russian Journal of Cardiology (2023) Vol. 28, Iss. 5, pp. 5471-5471
Open Access | Times Cited: 98
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Alison K. Wright, Matthew Carr, Evangelos Kontopantelis, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 909-918
Open Access | Times Cited: 94
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
Arnaud D. Kazé, Min Zhuo, Seoyoung C. Kim, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 91
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
Revista Española de Cardiología (2022) Vol. 75, Iss. 6, pp. 523.e1-523.e114
Closed Access | Times Cited: 89
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
Gerasimos Filippatos, Javed Butler, Dimitrios Farmakis, et al.
Circulation (2022) Vol. 146, Iss. 9, pp. 676-686
Open Access | Times Cited: 83
Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease
Carolyn Guan, Salman Zahid, Anum Minhas, et al.
Fertility and Sterility (2022) Vol. 117, Iss. 5, pp. 924-935
Open Access | Times Cited: 81
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 79

Scroll to top